Provectus CEO converts note into 132,160 shares

The preferred shares are convertible into 10 common shares each and are scheduled to convert automatically on December 31, 2028, unless converted earlier.

Rhea-AI Filing Summary

Provectus Biopharmaceuticals CEO and director Edward Pershing reported that an 8% unsecured convertible promissory note automatically converted on October 3, 2026, into 13,216 Series D-1 preferred shares at $2.862 per share. The preferred shares were converted into 132,160 common shares, bringing his reported direct common-stock holdings to 2,975,925 shares. Each preferred share is convertible into 10 common shares, and the preferred stock is scheduled to convert automatically on December 31, 2028, unless converted earlier. No Rule 10b5-1 plan is reported.

Insider Trade Summary

13,216 shares exercised/converted

Exercise 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note F3, F4	--	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock F1, F2	13,216	$0.00	$0.00

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 contracts (Direct); Series D-1 Convertible Preferred Stock — 2,975,925 contracts (Direct)

Footnotes (4)

1. F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. F3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. F4. On October 03, 2026, the 2025 Note converted into 13,216 shares of Series D-1 Preferred Stock.

Key Figures

Series D-1 preferred shares received: 13,216 shares Conversion price: $2.862 per share Common shares from preferred conversion: 132,160 shares +3 more

6 metrics

Series D-1 preferred shares received 13,216 shares Converted from the note on October 3, 2026

Conversion price $2.862 per share Price for conversion of the 2025 Note into Series D-1 preferred stock

Common shares from preferred conversion 132,160 shares Underlying common shares reported on October 3, 2026

Direct common-stock holdings after transaction 2,975,925 shares Reported resulting position

Preferred-to-common conversion ratio 10 common shares per preferred share Series D-1 preferred stock terms

Note interest rate 8% Unsecured convertible promissory note

Key Terms

8% unsecured convertible promissory note, Series D-1 Convertible Preferred Stock, Certificate of Designation

3 terms

8% unsecured convertible promissory note financial

"the 8% unsecured convertible promissory note (the "2025 Note")"

Series D-1 Convertible Preferred Stock financial

"shares of Series D-1 Preferred Stock"

Certificate of Designation financial

"terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the PVCT Series D-1 preferred stock conversion ratio?

Each Series D-1 preferred share is convertible into 10 common shares. The preferred stock is scheduled to convert automatically on December 31, 2028, unless converted earlier in accordance with the Certificate of Designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 10:52 AM Accepted by SEC EDGAR 10/05/2026 - 10:52 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	10/03/2026		M			$35,000	10/03/2025	10/03/2026	Series D-1 Convertible Preferred Stock(3)(4)	13,216	$0	$705,000	D
Series D-1 Convertible Preferred Stock	(1)	10/03/2026		M		13,216		10/03/2026	(2)	Common Stock	132,160	$0	2,975,925	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On October 03, 2026, the 2025 Note converted into 13,216 shares of Series D-1 Preferred Stock.

	/s/ Ed Pershing	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)